Neovasc to Sponsor Symposium on Treating Patients with Refractory Angina at TCT Connect 2020
Neovasc Inc. (NVCN) has announced its sponsorship of a symposium titled “Unmet Need in Treating Patients With Refractory Angina” at the 2020 TCT Connect Online Conference from October 14-18. The symposium will address the growing incidence of refractory angina, which affects 600,000 to 1.8 million Americans. Neovasc's product, the Reducer, is CE-marked in Europe for treating this condition, although it is not yet available in the U.S. The FDA granted the Reducer Breakthrough Device designation in October 2018, highlighting its potential for significant advantages in treatment.
- Neovasc's Reducer is CE-marked in Europe for treating refractory angina.
- The Reducer received FDA Breakthrough Device designation in October 2018, signaling strong potential.
- The Reducer is not approved for commercial use in the U.S.
- Refractory angina has a significant incidence, indicating a substantial market need that remains unmet.
VANCOUVER and MINNEAPOLIS, Oct. 13, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that it will sponsor a symposium entitled “Unmet Need in Treating Patients With Refractory Angina” at the 2020 TCT Connect Online Conference, taking place October 14-18, 2020.
The training session will be available via the TCT Connect e-satellite for registered participants beginning Friday, October 16, at 7 AM EDT. The session will feature presentations by:
· Prof. Tommaso Gori, MD, PhD, University Medical Center of Mainz, Germany.
· Timothy D. Henry, MD, Lindner Family Distinguished Chair in Clinical Research and Medical Director of The Carl and Edyth Lindner Center for Research at The Christ Hospital, Cincinnati, OH.
· Prof. Jonathan Michael Hill, Consultant Interventional Cardiologist at Royal Brompton & Harefield NHS Foundation Trust, London, U.K.
· Gregg W. Stone, MD, Senior Faculty, Medicine, Cardiology, Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, and Director, Academic Affairs, Mount Sinai Heart, New York, N.Y.
· Prof. Stefan Verheye, MD, PhD, Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium.
About Reducer
The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing. The Reducer provides relief of angina symptoms by altering blood flow within the myocardium of the heart and increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Placement of the Reducer is performed using a minimally invasive transvenous procedure that is similar to implanting a coronary stent and is completed in approximately 20 minutes.
While the Reducer is not approved for commercial use in the United States, the FDA granted Breakthrough Device designation to the Reducer in October 2018. This designation is granted by the FDA in order to expedite the development and review of a device that demonstrates compelling potential to provide a more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases. In addition, there must be no FDA approved treatments presently available, or the technology must offer significant advantages over existing approved alternatives.
Refractory angina, resulting in continued symptoms despite maximal medical therapy and without revascularization options, is estimated to affect 600,000 to 1.8 million Americans, with 50,000 to 100,000 new cases per year.1
1T. J. Povsic, S. Broderick, K. J. Anstrom et al., “Predictors of long-term clinical endpoints in patients with refractory angina,” Journal of the American Heart Association, vol. 4, no. 2, article e001287, 2015.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States (2 U.S. patients have been treated under Compassionate Use) and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com. Click here for a link to the most recent corporate update.
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.866.4012
Sean.Leous@westwicke.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words "expect", "anticipate", "estimate", "may", "will", "should", "intend," "believe", and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, the occurrence of and attendance at the E-Training session, expectations as to the future growth of the Company, the expansion of its product range and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in the Management's Discussion and Analysis for the three and six months ended June 30, 2019 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What is Neovasc Inc. sponsoring at the 2020 TCT Connect Online Conference?
What is the significance of the Reducer device?
When did the FDA grant Breakthrough Device designation to the Reducer?
How many Americans are affected by refractory angina?
Is the Reducer commercially available in the United States?
